In HealthTech, deals stall behind compliance reviews, multi-stakeholder approvals, and long sales cycles. Here is where your pipeline goes to die — and how to catch it before the quarter closes.
Who This Hits Hardest
This persona manages complex, multi-stakeholder buying processes and is most exposed to the ghost deal patterns specific to HealthTech. When a deal goes dark, this role bears the cost — in missed quota, in misleading forecasts, and in conversations with their own leadership about why the pipeline number was wrong.
What It Looks Like
A healthtech platform selling clinical workflow software had four deals stuck in a HIPAA compliance review cycle — none of the reps had a direct contact in the compliance department. The deals were all being held by a clinical champion who had no authority over the compliance decision. One deal was unblocked by identifying the Chief Compliance Officer directly and scheduling a 20-minute call. The other three were eventually confirmed as dead after the compliance team revealed they had already selected a competing solution.
These are the phrases that appear most frequently in ghost deal CRM activity logs for this vertical. Beneath each one is what the signal actually means — and why it usually means the deal is in trouble.
"Our clinical leadership team needs to sign off on this vendor"
What it really means
Clinical leadership moves slowly and has many competing priorities. If your champion has not already established a relationship with the clinical sign-off stakeholders, the deal is waiting on a meeting that has not been scheduled.
"HIPAA compliance review is currently underway — no approvals until it clears"
What it really means
HIPAA reviews are black boxes to vendors. You have no visibility into the timeline, the questions being asked, or the decision criteria. Without a contact inside the compliance process, this deal is in limbo.
"We are waiting on the outcome of our partnership with another vendor first"
What it really means
Another vendor has become a dependency for your deal. If that partnership succeeds, your deal may get reprioritized. If it fails, your deal will get shelved along with it. You are not the buyer here — you are a footnote.
HealthTech is structurally predisposed to ghost deals. The combination of long sales cycles, multi-stakeholder approval requirements, and complex internal review processes means deals can stall without any visible signal in the CRM. A deal can be in "Proposal" or "Negotiation" for 60+ days without a single person on the buying side having done anything to advance it.
The median HealthTech deal is 118 days — enough time for a champion to leave, a budget to be locked, an approval process to stall, or a competing vendor to get added to the evaluation. In most cases, none of these events are logged in the CRM. The deal just sits there, looking healthy to anyone who has not spoken to the buyer in 30 days.
What makes this especially expensive in HealthTech is the deal size. With a median ACV of $140K, each ghost deal represents significant revenue that is not in any real forecast — it is just inflating a number that will look good in the weekly pipeline review and terrible at the end of the quarter.
The three ghost phrases above are the leading indicators. But there are earlier signals worth monitoring before a deal goes fully dark: a champion who stops forwarding emails, a meeting that keeps getting rescheduled, a buyer who asks for documentation instead of a call, or a contact who starts routing you through an assistant instead of responding directly.
In HealthTech, the approval chain is often the ghost deal trigger. When a deal moves from a single champion to a multi-person approval process — compliance, legal, finance, or a committee — the deal velocity drops by 60–80% on average. A deal that was moving at one speed with one champion slows to committee speed the moment the approval process starts. If your deal has entered an approval phase and you have not established a direct contact with each approver, you are flying blind.
Budget cycles are another structural vulnerability. HealthTech companies often have fixed procurement cycles — annual, quarterly, or tied to fiscal events. A deal that misses the procurement window does not just delay; it often dies, because the budget gets reallocated and the evaluation has to restart from scratch in the next cycle. By then, your champion may have left, the business priority may have shifted, or a competitor has gotten a head start.
Revival starts with breaking through to the actual decision-maker or blocker — not just following up with the champion who has gone dark. In most cases, the champion has lost agency: they have hit the limits of their personal authority and cannot advance the deal without someone else in the organization. Emailing them more will not help.
The most effective revival tactic in HealthTech is to identify who owns the blocking decision — compliance, legal, finance, a committee, or a specific individual — and create a reason for them to engage directly. This usually means a new piece of content (a security one-pager, a legal FAQ, a ROI calculation tied to their specific business), not just another meeting request.
If the deal is truly dead — the blocker is not removable, the budget is gone, the champion has left — close it. Nothing corrupts a forecast faster than a rep who keeps a dead deal open "just in case." In HealthTech, where cycles are long and approvals are complex, the impulse to hold ghosts is even stronger than in faster-moving verticals. Push back on it. The forecast accuracy improvement from closing dead deals alone is often enough to move the number more than any single deal would have.
Run the Detector with a CSV of your deals — no sign-up required, results in 30 seconds. Or get the full forensic audit for a complete breakdown of what is stalling your pipeline and why.
No data stored. No follow-up without your consent.
Ready for a deal-by-deal breakdown? See the 14-Day Pipeline Diagnostic →